MedTrace Logo

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

NCT04566393 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-01-28

No results posted yet for this study

Summary

The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies.

Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.

Conditions

Interventions

DRUG

Ulixertinib (BVD-523)

Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor

Sponsors & Collaborators

  • Cancer Commons

    collaborator OTHER

  • xCures

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04566393 on ClinicalTrials.gov